Hydroxyurea megaloblastic anemia with

Hydroxyurea inhibits cell synthesis in the S phase of the DNA cycle. It is used selectively in the treatment of psoriasis, especially in those with liver disease who would be at risk of adverse effects with other agents. However, it is less effective than methotrexate. The typical dose is 1 g/day, with a gradual increase to 2 g/day as needed and as tolerated. Adverse effects include bone marrow toxicity with leukopenia or thrombocytopenia, cutaneous reactions, leg ulcers, and megaloblastic anemia. 

Hydroxyurea 1 g/day may increase to 2 g/day Bone marrow toxicity with leukopenia or thrombocytopenia, cutaneous reactions, leg ulcers, megaloblastic anemia... 

---